Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group.

Abstract:

:Anorexia and cachexia are common clinical problems of many patients with advanced cancer. Approximately 20 years ago, a controlled, clinical study demonstrated that dexamethasone could stimulate appetites of patients with advanced gastrointestinal cancer without causing any apparent effect on patient weight or survival. More recently, two double-blind, placebo-controlled trials investigated cyproheptadine and megestrol acetate in patients with cancer anorexia/cachexia. The first of these studies suggested that cyproheptadine could mildly stimulate appetite without causing any discernible effect on patient weight. Megestrol acetate, on the other hand, can clearly cause an increase in patient-perceived appetite and food intake and can also lead to substantial nonfluid weight gain in a proportion of patients with cancer anorexia/cachexia. Ongoing studies have been designed to better study the appetite-enhancing effects of megestrol acetate. In addition, current studies are evaluating the effect of the drug hydrazine sulfate on the appetite and weight status of patients with advanced lung or colon cancer.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Loprinzi CL,Ellison NM,Goldberg RM,Michalak JC,Burch PA

subject

Has Abstract

pub_date

1990-12-01 00:00:00

pages

8-12

issue

6 Suppl 9

eissn

0093-7754

issn

1532-8708

pii

0093-7754(90)90003-L

journal_volume

17

pub_type

临床试验,杂志文章,随机对照试验,评审
  • Screening diagnosis and staging of esophageal cancer.

    abstract::In geographic areas where there is a high risk of esophageal cancer, analysis of cells obtained from the esophagus has been used effectively to detect early lesions. This has been demonstrated on a large scale in studies from China. Using abrasive balloon cytology techniques, 75% of the cancers detected were early les...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Lightdale CJ,Winawer SJ

    更新日期:1984-06-01 00:00:00

  • Clinical experience with denileukin diftitox (ONTAK).

    abstract::Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. The human IL-2 receptor exists in three isoforms: low (CD25), intermediate (CD122/CD132), and high (CD25/CD122/CD132) affinity. The high-a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.12.017

    authors: Foss F

    更新日期:2006-02-01 00:00:00

  • Cyclooxygenase-2 inhibitors in colorectal cancer.

    abstract::Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory dr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00120-9

    authors: Stoehlmacher J,Lenz HJ

    更新日期:2003-06-01 00:00:00

  • Radiotherapy-induced salivary dysfunction.

    abstract::Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers. Notably, RT causes irreparable damage to salivary glands that increases the risk for severe and long-term oral and pharyngeal disorders. Several strategies in the treatment of head and neck cancers h...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.12.009

    authors: Ship JA,Hu K

    更新日期:2004-12-01 00:00:00

  • Recently identified peptides involved in the regulation of body weight.

    abstract::The application of molecular and genetic techniques to the study of body weight regulation have produced exciting new insights into the physiological systems governing energy expenditure, appetite, and metabolic signaling. A number of new peptides have been identified that play important roles in these regulatory syst...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bessesen DH,Faggioni R

    更新日期:1998-04-01 00:00:00

  • Infections in allogeneic bone marrow transplant recipients.

    abstract::Remarkable strides have been made in the management of infectious complications after bone marrow transplantation. Improved understanding of patterns of infection, the introduction of new antimicrobials, the advent of cytokines to enhance immune recovery, the development of better strategies to control graft-versus-ho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Wingard JR

    更新日期:1993-10-01 00:00:00

  • Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?

    abstract::Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.01.010

    authors: Odenike O,Thirman MJ,Artz AS,Godley LA,Larson RA,Stock W

    更新日期:2011-04-01 00:00:00

  • The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.

    abstract::Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metast...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1016/s0093-7754(01)90260-x

    authors: Coleman RE,Seaman JJ

    更新日期:2001-04-01 00:00:00

  • Preclinical experience with docetaxel in gastrointestinal cancers.

    abstract::Docetaxel is a semisynthetic taxane that acts primarily by promoting microtubule assembly and preventing the depolymerization of assembled microtubules, thereby inducing mitotic block and inhibition of cell proliferation. This agent also induces apoptosis and appears to prevent angiogenesis. Although docetaxel has sho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.002

    authors: Bekaii-Saab TS,Villalona-Calero MA

    更新日期:2005-04-01 00:00:00

  • Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.

    abstract::The median latency of 2 degrees MDS/AL is 4 to 5 years. A high percentage of patients with 2 degrees MDS/AL convert to 2 degrees AL. Survival of either is less than 1 year. A constellation of morphologic abnormalities from all 3 cell lines produces a unique appearance. Both 2 degrees MDS and 2 degrees AL are difficult...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Levine EG,Bloomfield CD

    更新日期:1992-02-01 00:00:00

  • The role of bone marrow transplantation in the non-Hodgkin's lymphomas.

    abstract::In a significant fraction of patients with NHL, disease develops that is resistant to conventional chemotherapy. Experience using high-dose chemotherapy, with or without TBI, and BMT is expanding. Remissions can be achieved in many patients with refractory NHL in particular those patients with tumors that are still ch...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Williams SF

    更新日期:1990-02-01 00:00:00

  • Novel strategies for the early detection and prevention of lung cancer.

    abstract::Lung cancer is the leading cause of cancer death in the United States. Despite evidence of molecular abnormalities in biological specimens, progress in this disease is hampered by the lack of diagnostic markers useful for clinical practice. The majority of patients with lung cancer are still diagnosed at an advanced s...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.02.009

    authors: Wardwell NR,Massion PP

    更新日期:2005-06-01 00:00:00

  • Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

    abstract::In the last decade our understanding of chronic lymphocytic leukemia (CLL) biology and pathogenesis has increased substantially. These insights have led to the development of several new agents with novel mechanisms of action prompting a change in therapeutic approaches from chemotherapy-based treatments to targeted t...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.02.007

    authors: Herman SE,Wiestner A

    更新日期:2016-04-01 00:00:00

  • Docetaxel and exisulind in hormone-refractory prostate cancer.

    abstract::Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0093-7754(01)90156-3

    authors: Ryan CW,Stadler WM,Vogelzang NJ

    更新日期:2001-08-01 00:00:00

  • The current status of toxicity protectants in cancer therapy.

    abstract::Current therapies for the treatment of malignancies are associated with significant toxicity, as chemotherapy and radiation therapy do not discriminate between normal and malignant cells. One approach to ameliorating the toxicity associated with therapy is through the use of chemoprotective agents. This article review...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schuchter LM,Luginbuhl WE,Meropol NJ

    更新日期:1992-12-01 00:00:00

  • Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.

    abstract::To improve the resectability and long-term local control of locally advanced rectal cancer, we have initiated a radiation dose-escalation trial. It is hoped that the radioprotector amifostine will sufficiently reduce rectal morbidity (without also reducing tumor response) to permit increasing radiation doses. Only 6 p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2002.37360

    authors: Myerson R,Zobeiri I,Birnbaum E,Dietz D,Fleshman J,Kodner I,Picus J,Ratkin G

    更新日期:2002-12-01 00:00:00

  • The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.

    abstract::The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.07.005

    authors: Wickerham DL,O'Connell MJ,Costantino JP,Cronin WM,Paik S,Geyer CE Jr,Ganz PA,Petrelli N,Mamounas EP,Julian TB,Wolmark N

    更新日期:2008-10-01 00:00:00

  • Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.

    abstract::Postmenopausal patients with advanced measurable and/or evaluable breast cancer entered a phase II trial of multiple agent cytotoxic therapy combined with endocrine therapy. Cycles of PNMF (prednimustine, novantrone, methotrexate, and 5-fluorouracil) were repeated every 4 weeks as follows: P, 100 mg/m2 PO on days 1 to...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Mouridsen HT,Andersson M,Pedersen L

    更新日期:1986-03-01 00:00:00

  • Pain management issues as part of the comprehensive care of the cancer patient.

    abstract::Pain is a common, feared, but treatable component of malignancy. The ability, however, to successfully relieve the difficult symptoms of progressive disease, including pain, require an understanding of tumor behavior, complications, and cancer therapy. Despite the treatability of cancer pain and multiple clinical opti...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Brescia FJ

    更新日期:1993-04-01 00:00:00

  • Maintaining bone health in prostate cancer throughout the disease continuum.

    abstract::Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metas...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.06.007

    authors: Saad F,Eastham J

    更新日期:2010-06-01 00:00:00

  • Practical aspects of delivering hereditary cancer risk counseling.

    abstract::The primary element involved in the practical delivery of hereditary cancer risk counseling is the development of a cancer genetics service. This service should involve a multidisciplinary core of specialists, aim to identify at-risk individuals and their families, and provide comprehensive genetic counseling with the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.07.003

    authors: DeMarco TA,Smith KL,Nusbaum RH,Peshkin BN,Schwartz MD,Isaacs C

    更新日期:2007-10-01 00:00:00

  • Liver-directed therapies in colorectal cancer.

    abstract::The liver is the most common site of metastatic colorectal cancer (CRC) and the status of this organ is an important determinant of overall survival in patients with advanced disease. Complete resection of hepatic CRC metastases can provide a long-term cure for some patients, but the majority of liver metastases are n...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.025

    authors: Ruan DT,Warren RS

    更新日期:2005-02-01 00:00:00

  • Hematopoietic growth factors in myelodysplastic syndromes.

    abstract::Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite the advent of disease-modifying therapies for MDS (eg, azacitidine, decitabine, and lenalidomide) and the current absence of an MDS-specific US Food and Drug Adm...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.04.014

    authors: Steensma DP

    更新日期:2011-10-01 00:00:00

  • Current treatment of medulloblastoma: recent advances and future challenges.

    abstract::Medulloblastoma (MB) is the most common malignant brain tumor of childhood, yet it makes up only 1% of adult brain tumors. MB is uniquely sensitive to chemotherapy and radiation, but successful surgical resection continues to be an important component of therapeutic success. Progress in the treatment of MB has occurre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.009

    authors: Rood BR,Macdonald TJ,Packer RJ

    更新日期:2004-10-01 00:00:00

  • Improving patient care through molecular diagnostics.

    abstract::Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assessment of lymph node status, and presence of metastasis. These are useful for initial evaluation, but are limited in their ability to predict response to treatment and/or ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.017

    authors: Perez EA,Pusztai L,Van de Vijver M

    更新日期:2004-10-01 00:00:00

  • Adjuvant therapy in rectal cancer: a protocol proposal.

    abstract::The use of adjuvant radiation therapy and chemotherapy diminishes the likelihood of local-regional and distant recurrences and appears to prolong survival in patients who have undergone a complete surgical resection of a Dukes-Kirklin stage B2 or C rectal cancer. Patients with this malignant condition rarely develop p...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Mayer RJ

    更新日期:1985-09-01 00:00:00

  • The association of malignancy with rheumatic and connective tissue diseases.

    abstract::This article reviews the associations of cancer with rheumatic diseases. Recent epidemiologic data linking the autoimmune connective tissue diseases with malignancy will be emphasized. Reports linking the occurrence of malignancy with rheumatoid arthritis, systemic lupus erythematosus, idiopathic inflammatory myopathy...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Carsons S

    更新日期:1997-06-01 00:00:00

  • The etiology of renal-cell carcinoma.

    abstract::Experimental renal-cell carcinoma can be induced by many different chemical carcinogens; dimethyl nitrosoamine has been most studied. The disease so induced in experimental animals closely resembles the spontaneous disease in man in histopathology, course, and other characteristics. Two agents that are probably etiolo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Outzen HC,Maguire HC Jr

    更新日期:1983-12-01 00:00:00

  • Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas.

    abstract::The results of adjuvant chemotherapy in high-grade gliomas are disappointing. Carmustine (BCNU) wafers placed in the resection cavity provide a modest increase in median survival. However, the overall benefit of this approach is small, it offers no potential for cure, and the results are not statistically significant ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.035

    authors: Grossman SA

    更新日期:2003-12-01 00:00:00

  • Is there a place for "dose-dense" weekly schedules of the taxoids?

    abstract::The recommended weekly dose and the maximum tolerated weekly dose of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) have yet to be determined. We report that a weekly dose of up to 40 mg/m2 docetaxel for 6 weeks is active in pretreated patients with metastatic breast cancer. From a preliminary study, this d...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Löffler TM

    更新日期:1998-10-01 00:00:00